Abstract
Purpose
As an autoimmune inflammatory disorder, active thyroid-associated ophthalmopathy (TAO) is managed optimally by immunosuppression. In this study, we aimed to evaluate octreotide scintigraphy and the level of serum extraocular muscle antibodies in TAO activity.
Patients and methods
This prospective study comprised 304 patients with active TAO (the clinical activity score; CAS≥3), 73 with inactive TAO (CAS<3), 128 with Graves’ disease (GD) without ophthalmopathy, and 100 healthy subjects. Moderate-to-severe active TAO patients (CAS≥5) received intravenous injection of methylprednisolone; mild active patients (3≤CAS≤4) received periocular injection of triamcinolone acetonide. 99Tcm-octreotide scintigraphy and serum levels of calsequestrin, uveal auto-antigen with coiled-coil domains and ankyrin repeats (UACA) and G2s antibodies were detected before and after treatment.
Results
99Tcm-octreotide scintigraphy was positive in active TAO patients (97%) with elevated uptake ratio (UR) (P<0.05), and showed a significant correlation with CAS (r=0.816, P<0.01). After treatment both UR and CAS decreased significantly (P<0.05). The receiving operator characteristic curve (ROC) showed that the best UR threshold for discriminating active and inactive TAO was 1.34 (sensitivity, 100%; specificity, 89.4%). The level of serum calsequestrin antibody was higher in active TAO (P<0.05), showed a significant correlation with CAS (r=0.738, P<0.05), and also decreased after treatment (P<0.05). The best serum calsequestrin antibody threshold of the ROC curve was 138 ng/l (sensitivity, 88.4%; specificity, 89.2%). The UACA antibody was elevated in both TAO and GD patients (P<0.05), with no significant difference (P>0.05). As to G2s, no significant difference was found between all groups (P>0.05). Moreover, six GD patients (4.69%) with elevated calsequestrin developed active TAO 12 weeks later.
Conclusion
99Tcm-octreotide scintigraphy played a critical role in the evaluation of the clinical activity and therapeutic efficacy of TAO. Autoimmunity against calsequestrin in the pathogenesis of the eye muscle components may provide further objective evidence of myopathy in active TAO. Furthermore, calsequestrin antibody may predict myopathy in active TAO.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bartalena L, Pinchera A, Marcocci C . Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21 (2): 168–199.
Tjiang H, Lahooti H, McCorquodale T, Parmar KR, Wall JR . Eye and eyelid abnormalities are common in patients with Hashimoto's thyroiditis. Thyroid 2010; 20 (3): 287–290.
Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS . Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol 2010; 55 (3): 215–226.
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158 (3): 273–285.
Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008; 18 (3): 333–346.
Werner SC . Classification of the eye changes of Graves' disease. Am J Ophthalmol 1969; 68 (4): 646–648.
Werner SC . Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol 1977; 83 (5): 725–727.
Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R . Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73 (8): 639–644.
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013; 98 (4): 1443–1449.
Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM . Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005; 62 (2): 145–155.
Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B et al. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease. J Nucl Med 2003; 44 (10): 1547–1555.
Krassas GE, Dumas A, Pontikides N, Kaltsas T . Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995; 42 (6): 571–580.
Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A . Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. J Nucl Med 1995; 36 (4): 550–554.
Rabinowitz MP, Carrasco JR . Update on advanced imaging options for thyroid-associated orbitopathy. Saudi J Ophthalmol 2012; 26 (4): 385–392.
Kaspar M, Archibald C, De BA, Li AW, Yamada M, Chang CH et al. Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy. Thyroid 2002; 12 (3): 187–191.
Tani J, Wall JR . Autoimmunity against eye-muscle antigens may explain thyroid-associated ophthalmopathy. CMAJ 2006; 175 (3): 239.
Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001; 98 (21): 12062–12067.
Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Wall JR . A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. Autoimmunity 1999; 29 (1): 1–9.
Gunji K, De Bellis A, Li AW, Yamada M, Kubota S, Ackrell B et al. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85 (4): 1641–1647.
Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B et al. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1999; 84 (4): 1255–1262.
Ohkura T, Taniguchi S, Yamada K, Nishio N, Okamura T, Yoshida A et al. Detection of the novel autoantibody (anti-UACA antibody) in patients with Graves' disease. Biochem Biophys Res Commun 2004; 321 (2): 432–440.
Zang S, Ponto KA, Kahaly GJ . Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011; 96 (2): 320–332.
Duan L, Li XF, Lu KY, Zhang CG, Hu G, Liu JZ et al. Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy. Zhonghua Yan Ke Za Zhi 2006; 42 (12): 1068–1072.
Dolman PJ . Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab 2012; 26 (3): 229–248.
Verity DH, Rose GE . Acute thyroid eye disease (TED): principles of medical and surgical management. Eye 2013; 27 (3): 308–319.
Mansi L, Rambaldi PF, Bizzarro A, Panza N, Di Martino S, De Bellis A et al. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos. Q J Nucl Med 1995; 39 (2): 105–110.
Kainz H, Bale R, Donnemiller E, Gabriel M, Kovacs P, Decristoforo C et al. Image fusion analysis of 99 m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur J Nucl Med Mol Imaging 2003; 30 (8): 1155–1159.
Sun H, Jiang XF, Wang S, Chen HY, Sun J, Li PY et al. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO). Endocrine 2007; 31 (3): 305–310.
Villadolid MC, Yokoyama N, Izumi M, Nishikawa T, Kimura H, Ashizawa K et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995; 80 (9): 2830–2833.
Gopinath B, Musselman R, Beard N, El-Kaissi S, Tani J, Adams CL et al. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease. Clin Exp Immunol 2006; 145 (1): 56–62.
Nguyen B, Gopinath B, Tani J, Wescombe L, Wall JR . Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy. Autoimmunity 2008; 41 (5): 372–376.
De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C et al. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 2012; 41 (2): 320–326.
Acknowledgements
This research was supported by the Natural Science Foundation of Shanxi Province, Grant No. 2013011059-2. We thank Xianfeng Li, MD, PhD, from the First Hospital of Shanxi Medical University for help with 99Tcm-octreotide scintigraphy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Eye website
Supplementary information
Rights and permissions
About this article
Cite this article
Sun, B., Zhang, Z., Dong, C. et al. 99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy. Eye 31, 668–676 (2017). https://doi.org/10.1038/eye.2017.42
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2017.42
This article is cited by
-
The risk factors for Graves’ ophthalmopathy
Graefe's Archive for Clinical and Experimental Ophthalmology (2022)
